Product News

Forest Laboratories, Inc. (NYSE: FRX) today announced the results of a one-year, placebo-controlled study, which found that Aerospan(TM) (flunisolide HFA) Inhalation Aerosol, a newly formulated inhaled corticosteroid currently under review by the U.S. Food & Drug Administration, does not affect the growth of pre-adolescent children with mild asthma.

Forest Laboratories, Inc. (NYSE: FRX) announced today that it has received an approvable letter from the United States Food and Drug Administration (FDA) to expand the use of Lexapro(TM) (escitalopram oxalate) to include the treatment of generalized anxiety disorder (GAD). Lexapro is the newest and most selective serotonin reuptake inhibitor (SSRI), and is currently indicated for the initial and maintenance treatment of major depressive disorder. more...

Forest Laboratories, Inc. (NYSE: FRX) announced today the results of an eight-week study performed in the United States, which found that Lexapro(TM) (escitalopram oxalate) relieves the symptoms of major depressive disorder and helps patients achieve remission as effectively as Effexor(R) XR. In addition, Lexapro was significantly better tolerated than Effexor XR, with four times as many patients in the Effexor XR group discontinuing the study more...

Forest Laboratories, Inc. (NYSE: FRX), announced today that it had received notification from IVAX Pharmaceuticals, Inc. that it has filed an Abbreviated New Drug Application (ANDA) with a Paragraph IV Certification for a generic equivalent to Lexapro(TM).

Forest Laboratories, Inc. (NYSE: FRX) announced today that it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration to expand the labeling of Lexapro(TM) (escitalopram oxalate) to include the treatment of panic disorder. Lexapro is the newest and most selective serotonin reuptake inhibitor (SSRI) indicated for the initial and maintenance treatment of major depressive disorder.

About more...

Forest Laboratories, Inc. (NYSE: FRX) announced today that it has submitted a New Drug Application (NDA) for memantine, an investigational Alzheimer's agent, to the U.S. Food and Drug Administration (FDA) seeking an indication for the treatment of moderate-to-severe Alzheimer's Disease. The new and amended NDA corrects minor structural and formatting deficiencies identified in a previous submission to the FDA's Division of Neuropharmacological more...

Forest Laboratories, Inc. (NYSE: FRX) announced that initial results from the first-ever U.S. clinical trial to evaluate a combination therapy for Alzheimer's disease were presented today at a major meeting of neurology, psychiatry and pharmacology experts.

Forest Laboratories, Inc. (NYSE: FRX) announced today that it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration to expand the labeling of Lexapro(TM) (escitalopram oxalate) to include the treatment of generalized anxiety disorder (GAD). The sNDA is based on three placebo-controlled studies in patients suffering from GAD.

Forest Laboratories, Inc. (NYSE: FRX) announced today that the U.S. Food and Drug Administration (FDA) concluded the Company's New Drug Application for its investigational treatment oxycodone HCl/ibuprofen was approvable. Oxycodone HCl/ibuprofen is a patented combination of oxycodone, an opioid analgesic, and ibuprofen, one of the most widely used non-steroidal anti-inflammatory drugs. Oxycodone HCl/ibuprofen is licensed to Forest Laboratories more...

Forest Laboratories, Inc., (NYSE: FRX) announced today that Lexapro(TM) (escitalopram oxalate), a powerful, effective and well-tolerated selective serotonin reuptake inhibitor (SSRI), is now available in pharmacies nationwide. Lexapro, the single active isomer of Celexa(TM) (citalopram HBr), was approved by the U.S. Food and Drug Administration (FDA) for the treatment of major depressive disorder on August 14, 2002. On August 29, the more...

Forest Laboratories, Inc. (NYSE: FRX) announced today that the U.S. Food and Drug Administration (FDA) has approved new labeling for Lexapro(TM) (escitalopram oxalate) as maintenance treatment for patients with major depressive disorder. Lexapro, a selective serotonin reuptake inhibitor (SSRI), is the single-isomer of Celexa(TM) (citalopram HBr).

Forest Laboratories, Inc. (NYSE: FRX) -- The announcement this morning in a small number of local TV markets by CBS affiliates that Forest Laboratories' Lexapro(TM) had been approved by the FDA was inadvertently released due to an error by CBS. In fact, as Forest Laboratories' Chairman stated at the Annual Shareholder's Meeting yesterday, Forest is in late stage labeling discussion with the FDA and is expecting action by the Agency in the near more...